Categories of study subjects
| MPD . | Non-MPD . | ||
|---|---|---|---|
| BM fibrosis . | No fibrosis . | BM fibrosis . | No fibrosis . |
| IMF (n = 15) | CML (n = 5) | T-cell lymphoma (n = 2) | Aplastic anemia (n = 6) |
| Lymphoma (n = 8) | |||
| ET/IMF (n = 8) | ET (n = 10) | Myeloma (n = 8) | Pure red cell aplasia (n = 4) |
| Myeloma (n = 5) | |||
| CML (n = 6) | PV (n = 4) | Chronic lymphocytic leukemia (n = 4) | |
| PV (n = 5) | |||
| MPD . | Non-MPD . | ||
|---|---|---|---|
| BM fibrosis . | No fibrosis . | BM fibrosis . | No fibrosis . |
| IMF (n = 15) | CML (n = 5) | T-cell lymphoma (n = 2) | Aplastic anemia (n = 6) |
| Lymphoma (n = 8) | |||
| ET/IMF (n = 8) | ET (n = 10) | Myeloma (n = 8) | Pure red cell aplasia (n = 4) |
| Myeloma (n = 5) | |||
| CML (n = 6) | PV (n = 4) | Chronic lymphocytic leukemia (n = 4) | |
| PV (n = 5) | |||
Patients with PV, grouped under BM fibrosis, were transformed and then included in the study at 3-4+ fibrosis. ET/IMF, 3-4+ fibrosis indicates that patients categorized as having ET/IMF most likely had IMF with thrombocythemia that developed into ET.63 SP-IR levels in the sera of patients with ET with no evidence of reticulin fibers were less than 5 pg/mL.